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Maria G. Daidone1† and Valentina Appierto1*†
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4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), an active polar metabolite of the
synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR), was shown to exert promising
antitumor activity through at least two independent mechanisms of action. Specifically,
differently from 4-HPR and other retinoids, 4-oxo-4-HPR targets microtubules and
inhibits tubulin polymerization causing mitotic arrest and on the other hand, analogously
to the parent drug, it induces apoptosis through the activation of a signaling cascade
involving the generation of reactive oxygen species (ROS). However, the potential in vivo
use of 4-oxo-4-HPR is impaired by its poor solubility. By chemical modification of 4-oxo-
4-HPR, a new class of compounds with improved solubility and in vivo bioavailability
was obtained. We demonstrated here that, among them, the most promising molecule,
sodium 4-carboxymethoxyimino-(4-HPR), was endowed with in vitro antitumor efficacy
and entirely preserved the double mechanism of action of the parent drug in cancer
cells of different histotypes. In fact, the retinoid induced the activation of the apoptotic
cascade related to the generation of ROS through endoplasmic reticulum stress
response and upregulation of phospho c-Jun N-terminal kinases and PLAcental
Bone morphogenetic protein, leading to cell death through caspase-3 cleavage.
Otherwise, sodium 4-carboxymethoxyimino-(4-HPR) caused a marked mitotic arrest
coupled with multipolar spindle formation and tubulin depolymerization. To assess
the compound antitumor activity, in vivo experiments were performed in three mouse
xenograft models (ovarian and breast cancers and mesothelioma). The in vivo results
demonstrated that retinoid administration as single agent significantly increased the
survival in ovarian cancer xenografts, induced a statistically significant decrease in
tumor growth in breast cancer xenografts, and caused a 30% reduction in tumor
growth in a mesothelioma mouse model. Even though further studies investigating
sodium 4-carboxymethoxyimino-(4-HPR) toxicity and in vitro and in vivo activities in
combination with other drugs are required, the double mechanism of action of the
retinoid coupled with its in vivo antitumor efficacy and potential low toxicity suggest
a promising therapeutic potential for the compound in different solid tumors.
Keywords: retinoids, sodium 4-carboxymethoxyimino-(4-HPR), solid tumors, antimitotic agent, apoptosis, ROS,
tubulin
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INTRODUCTION
Among retinoids, natural and synthetic derivatives of vitamin
A (retinol), fenretinide or N-(4-hydroxyphenyl)retinamide (4-
HPR) (Nagy et al., 1998) has given interesting results for
preneoplastic (Tradati et al., 1994; Moglia et al., 1996; Chiesa
et al., 2005) and neoplastic disorders (De Palo et al., 2002;
Veronesi et al., 2006). 4-oxo-N-(4-hydroxyphenyl)retinamide (4-
oxo-4-HPR) is a polar metabolite of 4-HPR, identified by our
group in plasma samples of 4-HPR-treated patients and in the
culture medium of 4-HPR-treated cancer cells. 4-oxo-4-HPR
elicited antiproliferative and apoptotic effects in various cancer
cell lines (e.g., neuroblastoma, ovarian and breast cancer cell
lines) and it was two to four times more effective than 4-HPR in
inhibiting cell growth (Villani et al., 2004). Interestingly, 4-oxo-
4-HPR was also effective in 4-HPR-resistant cancer cells and, in
combination with 4-HPR, displayed a synergistic effect (Villani
et al., 2006). Our molecular studies have demonstrated that 4-
oxo-4-HPR antitumor effect was due to at least two independent
mechanisms of action (Tiberio et al., 2010). Specifically, 4-oxo-
4-HPR, unlike 4-HPR and other retinoids, inhibited tubulin
polymerization, causing a marked accumulation of cells in
mitotic phase, resulting in aberrant spindle formation (i.e.,
multipolar organization without loss of centrosome integrity)
(Appierto et al., 2009a). On the other hand, similarly to 4-HPR, 4-
oxo-4-HPR caused apoptosis through the activation of a signaling
cascade starting from the generation of reactive oxygen species
(ROS) and involving the endoplasmic reticulum (ER) stress
response, the activation of Jun N-terminal Kinase (JNK) and
the PLAcental Bone morphogenetic protein (PLAB) upregulation
(Tiberio et al., 2010). The ability of 4-oxo-4-HPR to act through
at least two unrelated mechanisms could provide an explanation
of its higher antitumor activity compared to the parent drug
thus potentially making it a promising anticancer agent able to
counteract the development of drug resistance.
However, in in vivo experiments conducted in nude
mice (Musso et al., 2016), 4-oxo-4-HPR accumulated at
the injection site and drug plasma levels reached low
and variable concentrations, probably due to the poor
solubility of this compound. In the attempt to improve
solubility and bioavailability of 4-oxo-4-HPR, we have
modified the chemical structure of the drug, obtaining
a new class of compounds with higher solubility but
preserving the antitumor activity of the parent drug (Musso
et al., 2016). The most promising compound of this class,
3-[8-(4-Hydroxyphenylcarbamoyl)-3,7-dimethylocta-1,3,5,7-
tetraenyl]-2,4,4-trimethylcyclohex-2-enylideneaminooxy
sodium acetate or sodium 4-carboxymethoxyimino-(4-HPR)
(Figure 1), has shown to induce a significant cycle arrest in G2-M
coupled with growth inhibition and accumulation of cells in
sub-G1 in A2780 cell line (Musso et al., 2016).
Moreover, by analyzing the in vivo solubility and
bioavailability in a mouse model, we verified that sodium
4-carboxymethoxyimino-(4-HPR) was more soluble than
4-oxo-4-HPR, reaching 60-fold higher plasma levels, even if
administered at half dose, with very low variability and without
evident signs of toxicity for the mice (Musso et al., 2016).
The present study was planned to dissect the molecular
mechanism of action of this new promising 4-HPR derivative
and to investigate its in vivo antitumor activity in solid tumors in
order to propose a new potential agent for cancer therapy. Here
we reported that the compound exerted its antitumor activity in
cancer cells of different histotypes trough the double mechanism
of action of the parent drug, and displayed in vivo antitumor
efficacy in different solid tumors.
MATERIALS AND METHODS
Cell Lines and Reagents
Cell lines, source and culture conditions are described in Table 1.
All cell lines were cultured in monolayer at 37◦C under 5% CO2.
Sodium 4-carboxymethoxyimino-(4-HPR), synthesized as
previously described (Musso et al., 2016), was dissolved at
10 mmol/L in DMSO prior to further dilution in culture medium
and stored at −80◦C in the dark. Vinblastine (Sigma–Aldrich,
St. Louis, MO, USA) was dissolved at 1 mmol/L in water before
further dilution in culture medium and stored at 4◦C. Vitamin C
(Sigma, St. Louis, MO, USA) was added to cells 1 h before Sodium
4-carboxymethoxyimino-(4-HPR) treatment.
Growth Inhibition Assay
Cells were seeded in 96-well tissue culture plates at 7 × 103
cells/well and were allowed to adhere for 24 h before
treatment. Cells were grown in the presence of vehicle or
sodium 4-carboxymethoxyimino-(4-HPR) at a final
concentration of 0.3, 1, 3, 5, and 10 µM. Cellular growth
was assessed after 72 h by sulforhodamine B (SRB) assay, as
previously described (Tiberio et al., 2010). The antiproliferative
activity of the compound was tested in three independent
experiments with four replicate wells for each analysis.
Determination of Reactive Oxygen
Species
Intracellular production of ROS was assessed by employing
the oxidation-sensitive dye 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA;
Molecular Probes, Inc., Eugene, OR, USA) as described
previously (Villani et al., 2006) Briefly, 8 × 105 cells/well were
plated in six-well cell culture plates and incubated for 4 h in the
presence of 3 and 5 µM sodium 4-carboxymethoxyimino-(4-
HPR) and/or 100 µM vitamin C. Medium was discarded and,
under low light conditions, replaced with 50 µM CM-H2DCFDA
in whole medium for 20 min at 37◦C. Cells were harvested,
transferred to foil-wrapped tubes and analyzed immediately
by flow cytometry. The ROS generation was tested in three
independent experiments with three replicates for each sample
in each analysis.
Immunoblot Analysis
Proteins were extracted by using sodium dodecyl sulfate (SDS)
sample buffer (62.5 mM Tris–HCl [pH 6.8], 2% SDS) containing
1 mM phenylmethylsulfonyl fluoride, 10 µg/mL pepstatin,
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FIGURE 1 | Structures of 4-oxo-4-HPR and sodium 4-carboxymethoxyimino-(4-HPR). The chemical structures of 4-oxo-4-HPR (Left) and of its new
derivative (Right) are depicted.
TABLE 1 | Cell lines and culture conditions.
Cell line Source Culture medium
Ovarian cancer:
A2780 Obtained from Dr. Ozols, Bethesda, MD, USA RPMI 1640 + 10% FCS
IGROV-1 Obtained from Dr. Bénard, Villejuif, France RPMI 1640 + 10% FCS
SKOV-3 Purchased from ATCC, Manassas, VA, USA RPMI 1640 + 10% FCS
Breast cancer:
T47-D Obtained from Dr. R. Sutherland, Sydney, NSW, Australia RPMI 1640 + 10% FCS + 0.25 unit/mL insulin
BT-474 Purchased from ATCC, Manassas, VA, USA RPMI 1640 + 10% FCS
MDA-MB-231 Obtained from Dr. R. Sutherland, Sydney, NSW, Australia RPMI 1640 + 10% FCS
Neuroblastoma:
SK-N-BE Purchased from ATCC, Manassas, VA, USA RPMI 1640 + 10% FCS
SH-SY5Y Purchased from ATCC, Manassas, VA, USA RPMI 1640 + 10% FCS
SK-N-SH Purchased from ATCC, Manassas, VA, USA E-MEM + 10% FCS
Mesothelioma:
STO Established by our group from surgical specimens of patients who underwent surgery at INT∗ DMEM F12 + 10% FCS
MESO Established by our group from surgical specimens of patients who underwent surgery at INT∗ DMEM F12 + 10% FCS
FCS, fetal calf serum; ATCC, American Type Culture Collection; INT, Fondazione IRCCS Istituto Nazionale dei Tumori of Milan. ∗Zaffaroni et al. (2007).
12.5 µg/mL leupeptin, 2 µg/mL aprotinin, 1 mM sodium
orthovanadate, and 1 mM sodium molybdate. Proteins were
processed for western immunoblotting as previously described
(Appierto et al., 2004). The following antibodies used for
immunoblotting were purchased from the indicated suppliers
and used according the manufacturer testing conditions: PLAB
and pJNK from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); cleaved caspase-3 and pEIF2α from Cell Signaling
(Beverly, MA, USA); and GAPDH, α-tubulin, and actin from
Sigma–Aldrich. Quantification of pJNK and pEIF2α band
intensities was performed using the ImageJ software freely
available at http://rsb.info.nih.gov/ij/. Values were normalized by
actin band intensity.
Tubulin Polymerization Assay
Cells were seeded in 24 mm Petri dishes and the day
after were exposed to different concentration of sodium
4-carboxymethoxyimino-(4-HPR) and vinblastine and 24 h
later processed for the tubulin polymerization assay as
previously described (Cappelletti et al., 2004; Appierto
et al., 2009a). Cytosolic and cytoskeletal-associated proteins
were separated by SDS–PAGE and tubulin distribution
was analyzed by immunoblotting using α-tubulin antibody
(Sigma–Aldrich).
Cell Cycle Analysis
Analyses of cell cycle distribution were conducted as previously
described by our group (Tiberio et al., 2010) after 24 h of
treatment with 3 and 5 µM sodium 4-carboxymethoxyimino-
(4-HPR) and/or 100 µM vitamin C. Cell cycle analysis was
performed using FACScan flow cytometer (Becton Dickinson,
San Jose, CA, USA). The percentage of cells in different
phases of cell cycle was determined by ModFit LT cell cycle
analysis software (Verity Software House, Topsham, ME, USA),
considering only cells with DNA content ≥2n. Apoptotic cells
were identified as a sub-G1 population (DNA content<2n).
Immunofluorescence Analysis
Cells, grown on glass coverslip slides in 24 mm Petri dishes, were
fixed in 100% methanol at−20◦C for 7 min, washed with PBS and
then blocked at room temperature for 1 h in 3% BSA/ 0.1% (v/v)
Triton X-100/PBS. Cells were incubated overnight at 4◦C with
Frontiers in Pharmacology | www.frontiersin.org 3 April 2017 | Volume 8 | Article 226
fphar-08-00226 April 26, 2017 Time: 16:51 # 4
Tiberio et al. Sodium 4-Carboxymethoxyimino-(4-HPR): A New Anticancer Agent
the primary antibody mouse anti-α-tubulin (Sigma–Aldrich),
washed three times with PBS, and then incubated for another
hour at room temperature with the secondary antibody anti-
mouse Alexa 488 (Molecular Probes, Inc., Eugene, OR, USA),
washed thrice with PBS and stained with Hoechst 33342. Slides
were mounted with Mowiol (Calbiochem, San Diego, CA,
USA), and viewed with a fluorescence microscope [images were
recorded with a Spot Insight digital camera (Delta Sistemi, Rome,
Italy) equipped with a system of image analysis (IAS 2000; Delta
Sistemi)].
Mouse Xenograft Models and In Vivo
Treatments
All mice were purchased from Charles River (Calco, Italy) and
maintained in laminar-flow rooms or individually ventilated
cages at constant temperature and humidity, with food and
water administered ad libitum. All the in vivo experiments were
approved by the Ethics Committee for Animal Experimentation
of the Fondazione IRCCS Istituto Nazionale Tumori of Milan
according to National and Institutional guidelines.
Three different mouse models have been employed: peritoneal
mesothelioma (STO cells), ovarian carcinoma (IGROV-1 in vivo
cell line, growing mainly as ascites and maintained by i.p.
serial passages of ascitic cells) and breast (MDA-MB-231 cells)
cancer. As regards to mesothelioma, nude mice were inoculated
s.c. with 10 × 106 STO cells, and treatment with sodium
4-carboxymethoxyimino-(4-HPR) began 1 day after tumor cell
inoculation (doses: 30 and 60 mg/kg i.p.; 5 days/week for
5 weeks; end of treatment: day 32). Tumor growth in the control
and treated groups were evaluated, and the differences were
statistically analyzed.
For the ovarian cancer model, nude mice were inoculated
i.p. with 2.5 × 106 IGROV-1 cells, and treatment began 1 day
after tumor cell inoculation (doses: 30, 60, and 90 mg/kg i.p.;
5 days/week for 3 weeks; end of treatment: day 18). Mice with
ovarian cancer were treated for only 3 weeks because IGROV-
1 tumor is characterized by rapid growth and accumulation of
ascites. For ethical reasons, mice were sacrificed as ascites became
evident (before impending death) and 50% of control mice were
sacrificed within day 20. The day of sacrifice was considered as the
day of death for calculating and statistically analyzing the survival
time of each group. In order to also evaluate ascitic growth (viable
tumor cells were counted using the trypan blue exclusion assay)
and tumor weight (TW), six additional mice were used: three
treated with 60 mg/kg i.p. of sodium 4-carboxymethoxyimino-
(4-HPR) (we decided to use an intermediate dosage) and three
control mice. Ascitic fluid and tumor tissues were collected
during the last week of treatment.
As third cancer model, 5 × 106 human breast cancer cells
(MDA-MB-231) were resuspended in PBS and mixed 1:1 (v/v)
with Matrigel (BD Biosciences, Bedford, MA, USA) and were
inoculated into the right second mammary fat pad (m.f.p.)
of NOD/SCID mice under anesthesia (ketamine–xylazine).
Treatment with the drug began 1 day after tumor cell inoculation
(dose: 90 mg/kg; 4 days/week for 7 weeks; end of treatment:
day 45). We decided to adopt for the breast cancer model a
different schedule of treatment (i.e., 4 instead of 5 days/week),
taking in consideration the different mouse strain employed and
a long-term treatment hypothesized for this experiment. Tumor
growth in the control and treated groups were evaluated, and the
differences were statistically analyzed.
For all the in vivo experiments, the drug was first dissolved
in DMSO, diluted in sterile water at final DMSO concentration
of 5% (higher dose), and then diluted in sterile water to
obtain the other doses. It was administered by i.p. route
and delivered at 10 mg/kg of body weight. Control mice
were treated with the same solvent as used to dissolve the
sodium 4-carboxymethoxyimino-(4-HPR). The animals were
examined thrice a week to check tumor growth, body weight
and any signs of toxicity. TW was calculated by the formula
TW
(
g
) = (d2 × D) /2 where d and D are the shortest and the
longest diameters, respectively, measured in centimeters. All the
experiments were conducted in duplicate, obtaining comparable
results.
Statistical Analysis
Differences between mean values were assessed by two-tailed
Student’s t-test and for survival analysis data were compared
with the log-rank test. The analyses were performed using
GaphPad Prism v.5.02 (GraphPad Software, La Jolla, CA, USA).
P-values< 0.05 were considered as statistically significant.
RESULTS
Sodium
4-Carboxymethoxyimino-(4-HPR) Inhibits
Cell Growth of Human Cancer Cell Lines
of Different Histotypes
The improvement in solubility obtained through the chemical
modification of 4-oxo-4-HPR (Musso et al., 2016), prompted us
to investigate the antitumor activity of this new derivative. The
growth-inhibitory effect of sodium 4-carboxymethoxyimino-(4-
HPR) was tested in a panel of human cancer cell lines of
different histotypes. The 50% effective cytotoxic concentrations
(EC50) after 72 h of treatment were calculated and reported
in Table 2. The compound showed an ability to inhibit
the cell growth similar to that of the parent drug 4-oxo-
4-HPR (Villani et al., 2006), in ovarian and breast cancer
cell lines and in peritoneal mesothelioma and neuroblastoma
cells.
Overall, these results indicate that sodium 4-
carboxymethoxyimino-(4-HPR) is a retinoid derivative effective
in inhibiting proliferation of cancer cells of different histotypes.
Sodium
4-Carboxymethoxyimino-(4-HPR)
Maintains the Mechanism of Action of
4-oxo-4-HPR in A2780 Cells
We have recently reported that the chemical modification
performed on 4-oxo-4-HPR and leading to sodium
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TABLE 2 | Antiproliferative activity of sodium
4-carboxymethoxyimino-(4-HPR) on solid tumor cell lines of different
histotypes.
Tumor cell lines EC50 (µM)
Ovary
A2780 2.78
IGROV-1 3.82
SKOV-3 5.96
Breast
T47-D 3.95
MDA-MB-231 3.97
BT-474 3.69
Neuroblastoma
SK-N-BE 1.55
SK-N-SH 1.9
SH-SY5Y 1.3
Mesothelioma
STO 1.48
MESO 1.28
4-carboxymethoxyimino-(4-HPR) did not impair the antimitotic
activity of the parental drug, in terms of cell cycle arrest and
formation of multipolar spindles (Musso et al., 2016). In the
present study we deeper dissected the activity of the compound
to investigate whether this drug entirely preserved the double
mechanism of action previously described for 4-oxo-4-HPR
(Appierto et al., 2009a; Tiberio et al., 2010). To this aim, we
first analyzed whether sodium 4-carboxymethoxyimino-(4-
HPR) induced the generation of ROS in A2780, a human
ovarian carcinoma cell line previously used as in vitro model
to investigate the mechanism of action of the parental drug
(Appierto et al., 2009a; Tiberio et al., 2010). The analysis
revealed that the molecule caused the generation of ROS
in a dose-dependent manner (Figure 2A). Treatment with
both 3 and 5 µM 4-carboxymethoxyimino-(4-HPR) for 24 h
caused a twofold increase in JNK phosphorylation, a slight
induction of pEIF2α (1.5-fold over control for both drug
doses), marked PLAB upregulation and caspase-3 cleavage
(Figure 2B), suggesting that sodium 4-carboxymethoxyimino-
(4-HPR) was able to induce the activation of the ROS-related
apoptotic cascade described for its parental drug (Tiberio
et al., 2010). On the other hand, the treatment led to a
marked dose-dependent accumulation of cells in the G2-M
phases, associated with abnormal mitotic spindles with loss
of normal bipolarity and formation of multipolar spindles,
as revealed by immunofluorescence labeling for α-tubulin
(Figure 3A).
To investigate whether the sodium 4-carboxymethoxyimino-
(4-HPR)-induced mitotic arrest and formation of multipolar
spindles were related to the ROS generation, the effects of
the antioxidant vitamin C on cell cycle perturbation and
formation of aberrant spindles induced by the compound
were analyzed. In A2780 cells exposed for 24 h to 5 µM
4-carboxymethoxyimino-(4-HPR), the addition of 100 µM
vitamin C abrogated ROS generation (Supplementary Figure S1)
FIGURE 2 | Sodium 4-carboxymethoxyimino-(4-HPR) is able to activate
the ROS-related apoptotic cascade. (A) Analysis of ROS production in
A2780 cells treated for 4 h with 3 and 5 µM of sodium
4-carboxymethoxyimino-(4-HPR). The graph shows representative flow
cytometry fluorescence profiles in different conditions of treatment (one
representative experiment of three). (B) A2780 cells treated for 24 h with 3
and 5 µM of sodium 4-carboxymethoxyimino-(4-HPR) were subjected to
western blot analysis for the expression of pJNK, pEIF2α, PLAB and cleaved
caspase-3. As a control for loading, the blots were incubated with actin
antibody.
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FIGURE 3 | Sodium 4-carboxymethoxyimino-(4-HPR) is endowed with antimitotic activity. (A) Flow cytometric analysis of propidium iodide-stained A2780
cells treated for 24 h with vehicle or 3 and 5 µM of sodium 4-carboxymethoxyimino-(4-HPR) with or without 100 µM vitamin C. Numbers in the figure indicate the
percentage of cells in the phase of cell cycle. One experiment representative of three is shown. On the bottom of each histogram, immunofluorescence analysis with
α-tubulin antibody (green) of cells treated in the same way. Nuclear morphology was visualized by staining with Hoechst 33342 (blue). Photos were taken at 40×
magnification. (B) Western blot analysis of soluble cytosolic (s) or polymerized (p) tubulin in A2780 cells after 24 h of exposure to vehicle, sodium 4
carboxymethoxyimino-(4-HPR), and vinblastine (tubulin depolymerizing agent).
and caused a reduction of sub-G1 population but did not
prevent the accumulation of G2-M cell population or the
formation of aberrant spindles (Figure 3A). The results
indicated that in A2780 cells, the mitotic arrest induced by
4-carboxymethoxyimino-(4-HPR) was independent from ROS
generation.
Finally, we investigated the effects of the 4-oxo-4-HPR
derivative on the microtubule system of A2780 cells treated
for 24 h with two different concentrations of the drug (i.e.,
3 and 5 µM). Similarly to 4-oxo-4-HPR (Appierto et al.,
2009a), sodium 4-carboxymethoxyimino-(4-HPR) decreased the
polymerized portion of tubulin in a dose-dependent manner,
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as revealed by western blot analysis of free and polymerized
tubulin (Figure 3B). Thus, the aberrant formation of mitotic
spindles caused by the drug could be ascribed to the
inhibition of microtubule polymerization induced by the retinoid
in cultured cells, as previously described for 4-oxo-4-HPR
(Appierto et al., 2009a). Taken together, our data indicated that
sodium 4-carboxymethoxyimino-(4-HPR) entirely maintained
the double mechanism of action of its parental drug in A2780 cells
(Figure 4).
Sodium
4-Carboxymethoxyimino-(4-HPR) Acts
through a Double Mechanism of Action
in Different Cancer Cell Lines
We next investigated whether the two mechanisms of action
of 4-carboxymethoxyimino-(4-HPR) described in A2780 were
recapitulated also in other human cancer cells responsive to
the retinoid. Specifically, we analyzed the upregulation of PLAB
and the cleavage of caspase-3 for the activation of the ROS-
induced apoptotic cascade and the accumulation in G2-M phases
of the cell cycle for the antimitotic activity in STO (mesothelioma
cells derived from a patient’s surgical specimen), IGROV-1
(ovarian cancer cell line), and MDA-MB-231 (triple negative
breast cancer cell line) cells. In the three analyzed cell lines,
the treatment with the drug induced both PLAB upregulation
and caspase-3 cleavage and a marked G2-M cell cycle arrest
(Figure 5). The results confirmed that the distinctive feature
of sodium 4-carboxymethoxyimino-(4-HPR) to have a double
mechanism of action in solid tumors was not restricted to A2780
cells but represented a distinctive mode of action of the drug
(Figure 4).
Sodium
4-Carboxymethoxyimino-(4-HPR) Is
Endowed with In Vivo Antitumor Activity
on Different Solid Tumor Models
Previous in vivo preliminary study demonstrated that, compared
to 4-oxo-4-HPR, sodium 4-carboxymethoxyimino-(4-HPR)
reached 60-fold higher plasma levels, with extremely low
variability and without apparent signs of toxicity for the
mice (Musso et al., 2016). This promising evidence led us to
investigate the antitumor activity of the compound in mouse
models. Specifically, mice xenografted with human mesothelioma
(STO), ovarian cancer (IGROV-1) and breast cancer (MDA-MB-
231) cells were employed. Mice with mesothelioma xenografts
were treated 5 days/week for 5 weeks with 30 or 60 mg/kg
i.p. of sodium 4-carboxymethoxyimino-(4-HPR). As shown
in Figure 6A, the treatment with the retinoid reduced the
tumor growth at both doses, although a statistical significance
was not reached. As regards to ovarian model, the mice were
treated 5 days/week for 3 weeks with 30, 60, and 90 mg/kg i.p.
of retinoid. Survival, TW and the number of ascitic cells were
evaluated. At the doses of 60 and 90 mg/kg, the drug significantly
increased the survival of the mice inoculated with IGROV-1 cells
(p < 0.01; Figure 6B). Consistently, solid tumor mass and the
FIGURE 4 | Mechanisms of action of sodium
4-carboxymethoxyimino-(4-HPR). Scheme showing proposed cascade of
events involved sodium 4-carboxymethoxyimino-(4-HPR)-induced growth
inhibitory effect.
number of ascitic cells were reduced in treated mice compared
to control group of 62% (on average g: 0.59 ± 0.13 SEM and
0.22 ± 0.055 SEM, respectively) and 90% (on average cells:
165.5 × 106 ± 68.40 × 106 SEM and 20.13 × 106 ± 15.74 × 106
SEM, respectively).
Based on the results obtained in the previous models, we
decided to test a single dose (90 mg/kg) for in vivo experiments
on the breast cancer model. Specifically, the mice were subjected
for 7 weeks to a 4 days/week treatment with the compound. As
shown in Figure 6C, the retinoid significantly reduced the tumor
growth of the triple negative breast cancer model (p= 0.01).
In all the experiments the compound administration was well
tolerated with maximum body weight loss of 9% restricted to the
first 3 days of treatment.
Overall our in vivo data demonstrated that sodium 4-
carboxymethoxyimino-(4-HPR) deserves further investigations
as a new potential anticancer drug able to exert its activity on
different solid tumor types.
DISCUSSION
4-oxo-4-HPR, a polar 4-HPR metabolite, was shown
to be a potential promising antitumor agent (Appierto
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FIGURE 5 | Sodium 4-carboxymethoxyimino-(4-HPR) acts through a double mechanism of action in different cancer cell lines. Left, flow cytometric
analysis of propidium iodide-stained tumor cells treated with vehicle or 3 and 5 µM of sodium 4-carboxymethoxyimino-(4-HPR) for 24 h. Numbers in the figure
indicate the percentage of cells in the phase of cell cycle. One experiment representative of three is shown. Right, the same treated cells were subjected to western
blot analysis for the expression of PLAB and cleaved caspase-3. As a control for loading, the blots were incubated with GAPDH antibody.
et al., 2009a; Tiberio et al., 2010) even though its poor
solubility limited in vivo testing (Musso et al., 2016). By
chemical modification of 4-oxo-4HPR we obtained a new
compound, sodium 4-carboxymethoxyimino-(4-HPR), with
improved solubility and in vivo bioavailability (Musso et al.,
2016).
The compound was effective in inhibiting the growth
of a panel of cancer cells of different histotypes, such as
ovarian and breast cancers, neuroblastoma and mesothelioma.
The antiproliferative activity was comparable to that observed
for 4-oxo-4-HPR and prompted us to evaluate whether
sodium 4-carboxymethoxyimino-(4-HPR) entirely preserved the
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FIGURE 6 | Sodium 4-carboxymethoxyimino-(4-HPR) exerts in vivo
antitumor activity on different tumor models. (A) Tumor growth curves of
mice xenografted with human mesothelioma cells (STO) and treated
5 days/week for 5 weeks (end of treatment: day 32) with vehicle or 30 and
60 mg/kg of sodium 4-carboxymethoxyimino-(4-HPR). (B) Survival analysis of
mice xenografted with human ovarian cancer cells (IGROV-1) and treated
5 days/week for 3 weeks (end of treatment: day 18) with vehicle or 30, 60,
and 90 mg/kg of sodium 4-carboxymethoxyimino-(4-HPR). (C) Tumor growth
curves of mice xenografted with human triple negative breast cancer cells
(MDA-MB-231) and treated for 4 days/week for 7 weeks (end of treatment:
day 45) with vehicle or 90 mg/kg of sodium 4-carboxymethoxyimino-(4-HPR).
mechanism of action of the parent drug. We previously
demonstrated that the 4-HPR derivative induced apoptosis via
the signaling cascade activated also by 4-HPR (ROS → ER
stress → JNK → PLAB) but, differently from the latter, also
acted as an antimicrotubule agent (Appierto et al., 2009a,b;
Tiberio et al., 2010). By investigating mechanisms of action
of the new compound in A2780 cell line we found that the
treatment with the retinoid caused the generation of ROS in
a dose-dependent manner. As a downstream effect, sodium
4-carboxymethoxyimino-(4-HPR) induced the activation of the
entire ROS-related apoptotic cascade through the ER stress
response (determined by the phosphorylation of EIF2α) and
the upregulation of pJNK and PLAB, leading to caspase-3
cleavage. The activation of this apoptotic pathway was not
restricted to A2780 cell line but was observed also in STO,
IGROV-1 and MDA-MB-231 cells. Similarly, in all tested cancer
cell lines, the compound induced a marked accumulation
of cells in G2-M phase in a dose-dependent manner. As
previously demonstrated for 4-oxo-4-HPR, the cell cycle arrest
was coupled with multipolar spindle formation and tubulin
depolymerization. Noteworthy, the mitotic arrest and the
coupled formation of multipolar spindles induced by sodium
4-carboxymethoxyimino-(4-HPR) were independent from the
ROS-related signaling cascade. In fact, inhibition of the ROS
generation by vitamin C did not prevent the ability of the
compound to exert its antimicrotubule activity.
Overall, our in vitro data demonstrated that sodium
4-carboxymethoxyimino-(4-HPR) entirely preserve the double
mechanism of action described for its parent drug (Figure 4). The
antimitotic activity of the drug makes it potentially promising
for the treatment of high-proliferating solid tumors (such as,
triple negative breast cancer). Moreover, we could speculate that
its ability to act through, at least, two unrelated pathways could
overcome the occurrence of resistance mechanism. However,
further preclinical studies are definitely needed to investigate
whether 4-carboxymethoxyimino-(4-HPR) could be effective in
the treatment of drug-resistant tumors and, in order to design
effective drug combination, to investigate how the two pathways
activated by the compound interact.
The antimicrotubule activity is a very atypical mechanism of
action for a retinoid. In fact, to the best of our knowledge, among
retinol derivatives only 4-oxo-4-HPR and its new derivative are
able to directly target tubulin. We previously hypothesized that
the introduction of a keto group in position 4 of the cyclohexene
ring of 4-HPR, leading to 4-oxo-4-HPR, was responsible for its
antimitotic activity. However, sodium 4-carboxymethoxyimino-
(4-HPR) has a different chemical group at the same position
(Figure 1). Thus, we could speculate here that the presence of
polar groups at position 4 has a key role for antitubulin activity.
Taking advantage of the previously demonstrated improved
bioavailability of the new derivative compared to 4-oxo-4-HPR
(Musso et al., 2016) we performed in vivo experiments in
three different mouse models (mesothelioma, ovarian, and breast
cancers) to assess its antitumor effect. The retinoid induced
statistically significant increase in survival and decrease in
tumor growth in ovarian (IGROV-1) and triple negative breast
cancer (MDA-MB-231) models, respectively. Interestingly, the
treatment efficacy obtained on the ovarian and breast cancer
models persisted several days after treatment cessation, allowing
us to speculate that an intermittent treatment schedule might be
effective for this compound to counteract tumor growth.
The treatment with sodium 4-carboxymethoxyimino-(4-
HPR) caused a 30% reduction in tumor growth in a mesothelioma
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mouse model but this effect was not statistically significant. In
spite of its in vitro doubling time, very similar to the other
tumor models (STO 24 h; IGROV-1 26 h; MDA-MB-231 22 h),
STO xenografts, contrary to the IGROV-1 and MDA-MD-231
xenografts displayed high variability in tumor growth, thus
plausibly affecting the evaluation of the statistical significance of
the test.
Considering that in clinical trials it has been found that
retinol derivatives (such as 4-HPR) cause less toxicity than
the classic chemotherapy agents (Miller, 1998), we could
hypothesize that a similar lack of severe side effects could be
obtained with sodium 4-carboxymethoxyimino-(4-HPR) as well.
In addition, the derivative was obtained through a modification
of the chemical structure of 4-oxo-4-HPR which was initially
discovered in plasma samples of women enrolled in a phase
III clinical trial and treated with 4-HPR for 5 years, that
experienced only nyctalopia (decreased night vision) as side effect
(Veronesi et al., 2006; Zanardi et al., 2006; Cazzaniga et al., 2012).
Although tolerability experiments are definitely needed, based
on the above-mentioned information and on our preliminary
in vivo observations, we expect that the toxicity of sodium
4-carboxymethoxyimino-(4-HPR) could be mild.
Notably, the demonstrated efficacy of the present drug against
ovarian and triple negative breast cancers could have important
clinical implications since these types of tumors are fast growing,
with very poor prognosis and usually treated with classical
chemotherapy drugs inducing severe side effects (Partridge et al.,
2001; Edwards, 2003; Markman, 2003; McWhinney et al., 2009;
De Iuliis et al., 2015), thus there is an urgent need to identify
novel anticancer agents and new combination therapies effective
and non-toxic. In this context, also considering the fast growth
of triple negative breast cancer, we could hypothesize to test
sodium 4-carboxymethoxyimino-(4-HPR) in combination with
other antimitotic agents currently used to treat this type of tumor
(such as taxanes) in order to definitely impair the cell cycle
division thus leading to cell death.
CONCLUSION
The present study demonstrated, for the first time, that sodium
4-carboxymethoxyimino-(4-HPR) is endowed with both in vitro
and in vivo antitumor activity in different solid tumors. Its
double mechanism of action coupled with its in vivo antitumor
activity and potential low toxicity suggest its possible use as
anticancer drug for different tumors and, specifically, for actively
proliferating cancers. Further studies investigating its toxicity and
in vitro and in vivo activities in combination with other drugs are
definitely required to understand whether the new 4-oxo-4HPR
derivative has an actual therapeutic potential.
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